3,4,4-三甲氧基哌啶-1-羧酸乙酯 | 83863-73-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 3,4,4-三甲氧基哌啶-1-羧酸乙酯
• 英文名称: ethyl 3,4,4-trimethoxypiperidine-1-carboxylate
• 英文别名: (-)-ethyl 3,4,4-trimethoxy-1-piperidinecarboxylate
• CAS: 83863-73-4
• 化学式: C₁₁H₂₁NO₅
• 分子量: 247.291
• InChiKey: IRFADAQNHJWEIN-UHFFFAOYSA-N

物化性质

• 沸点：
  301.7±42.0 °C(Predicted)
• 密度：
  1.11±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  57.2
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  3,4,4-三甲氧基哌啶-1-羧酸乙酯 在 盐酸 、 硫酸 、 palladium 10% on activated carbon 、 氢气 、 甲酸铵 、 三乙酰氧基硼氢化钠 、 碳酸氢钠 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 16.5h， 生成 ethyl (-)-cis-4-amino-3-methoxy-1-piperidinecarboxylate
  参考文献：
  名称：

  Optimization of Pyrrolamide Topoisomerase II Inhibitors Toward Identification of an Antibacterial Clinical Candidate (AZD5099)

  摘要：

  AZD5099 (compound 63) is an antibacterial agent that entered phase 1 clinical trials targeting infections caused by Gram-positive and fastidious Gram-negative bacteria. It was derived from previously reported pyrrolamide antibacterials and a fragment-based approach targeting the ATP binding site of bacterial type II topoisomerases. The program described herein varied a 3-piperidine substituent and incorporated 4-thiazole substituents that form a seven-membered ring intramolecular hydrogen bond with a 5-position carboxylic acid. Improved antibacterial activity and lower in vivo clearances were achieved. The lower clearances were attributed, in part, to reduced recognition by the multidrug resistant transporter Mrp2. Compound 63 showed notable efficacy in a mouse neutropenic Staphylococcus aureus infection model. Resistance frequency versus the drug was low, and reports of clinical resistance due to alteration of the target are few. Hence, 63 could offer a novel treatment for serious issues of resistance to currently used antibacterials.

  DOI：

  10.1021/jm500462x
• 作为产物：
  描述：

  N-乙氧羰基-4-哌啶酮 在 sodium hydride 、 potassium hydroxide 作用下， 以 四氢呋喃 、 mineral oil 为溶剂， 反应 15.5h， 生成 3,4,4-三甲氧基哌啶-1-羧酸乙酯
  参考文献：
  名称：

  [EN] LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES
  [FR] DÉRIVÉS DE N-(PIPÉRIDIN-4-YL)BENZAMIDE À ACTION LUMINALE

  摘要：

  本公开涉及公式1的化合物及其在药学上可接受的盐，其中m、R1、R2、R3、R4、R5、R6、X1、X2、X3和X4在规范中有定义。本公开还涉及制备公式1化合物的材料和方法，包含它们的药物组合物，以及它们用于治疗与5-HT4受体相关的疾病、疾病和症状的用途。

  公开号：

  WO2021225968A1

文献信息

• 3-Aminocyclopentanecarboxamides as Modulators of Chemokine Receptors
  申请人：Xue Chu-Biao

  公开号：US20070149532A1

  公开（公告）日：2007-06-28

  The present invention is directed to compounds of Formula I: I which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.

  本发明涉及化合物I的化合物：I，这些化合物是趋化因子受体的调节剂。本发明的化合物及其组合物在治疗与趋化因子受体表达和/或活性相关的疾病方面是有用的。
• Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
  申请人：Janssen Pharmaceutica N.V.

  公开号：US04962115A1

  公开（公告）日：1990-10-09

  Novel N-(3-hydroxy-4-piperidinyl)benzamides and derivatives thereof, said compounds being useful as stimulators of the motility of the gastro-intestinal system.

  新型N-(3-羟基-4-哌啶基)苯甲酰胺及其衍生物，所述化合物可用作促进胃肠系统运动的刺激剂。
• [EN] LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE N-(PIPÉRIDIN-4-YL)BENZAMIDE À ACTION LUMINALE
  申请人：TAKEDA PHARMACEUTICALS CO

  公开号：WO2021225968A1

  公开（公告）日：2021-11-11

  Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein m, R1, R2, R3, R4, R5, R6, X1, X2, X3 and X4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with the 5-HT4 receptor.

  本公开涉及公式1的化合物及其在药学上可接受的盐，其中m、R1、R2、R3、R4、R5、R6、X1、X2、X3和X4在规范中有定义。本公开还涉及制备公式1化合物的材料和方法，包含它们的药物组合物，以及它们用于治疗与5-HT4受体相关的疾病、疾病和症状的用途。
• Neuromuscular blocking agents
  申请人：Burroughs Wellcome Co.

  公开号：US05453510A1

  公开（公告）日：1995-09-26

  1R-cis,1'R-cis isomer of a 2',2'-(3,11-dioxo-4,10-dioxatridecylene)-bis(1,2,3,4-tetrahydro-6, 7-dimethoxy-2-methyl-1-veratrylisoquinolium) said, substantially free from other geometrical and optical isomers thereof. The 1R-cis,1'R-cis isomer has been found to have an advantageous combination of pharmacological properties, notably greater neuromuscular blocking potency, weaker histamine-releasing potency, and at equivalent levels of neuromuscular blockade, fewer potential adverse effects on the autonomic nervous system (sympathetic and parasympathetic blockage), in comparison with the known mixture of geometrical and optical isomers.

  一种2',2'-(3,11-二氧化-4,10-二氧杂十二烷基)-双(1,2,3,4-四氢-6,7-二甲氧基-2-甲基-1-维拉特利异喹啉)的1R-cis,1'R-cis同分异构体，基本上不含其他几何和光学同分异构体。已发现1R-cis,1'R-cis同分异构体具有有利的药理特性，特别是更强的神经肌肉阻滞效力，较弱的组胺释放效力，并且在相同水平的神经肌肉阻滞下，对自主神经系统（交感神经和副交感神经阻滞）的潜在不良影响较少，与已知的几何和光学同分异构体混合物相比。
• [EN] NOVEL PROCESS FOR THE PREPARATION OF CISATRACURIUM BESYLATE<br/>[FR] NOUVEAU PROCÉDÉ POUR LA PRÉPARATION DE BÉSYLATE DE CISATRACURIUM
  申请人：GLAND PHARMA LTD

  公开号：WO2010128518A2

  公开（公告）日：2010-11-11

  The present invention is related to a novel process for the preparation of cisatracurium besylate, more particularly optically and geometrically pure cisatracurium besylate in large scale.

  本发明涉及一种新型工艺，用于制备大规模的顺式阿曲库铵倍氯酸盐，更具体地说是光学和几何纯的顺式阿曲库铵倍氯酸盐。